stockrowSarepta Therapeutics, Inc.
SRPT Healthcare Biotechnology
Sarepta Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.2 billion, up 15.6% from fiscal 2024.
- Revenue
- −4.51%
- EPS
- +46.0%
- Free cash flow
- +231.8%
- Total debt
- −17.2%
Quarter to September 2026, against a year earlier
Follow SRPT
Alert me
Sarepta Therapeutics, Inc. (SRPT) EPS (diluted)
Sarepta Therapeutics, Inc.'s EPS (diluted) for fiscal 2025 was −$7.13, compared with $2.34 in fiscal 2024. Over the twelve months to 30 September 2026 it was −$1.37. Over the past ten years it has ranged from −$9.71 (fiscal 2019) to $2.34 (fiscal 2024); the current reading is higher than 27% of that period. Sarepta Therapeutics, Inc. ranks 259th of 580 Biotechnology companies by EPS (diluted).
EPS (diluted), annual
Embed this chart
Annual newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| FY2025 | −$7.13 | — |
| FY2024 | $2.34 | — |
| FY2023 | −$5.80 | — |
| FY2022 | −$8.03 | — |
| FY2021 | −$5.15 | — |
| FY2020 | −$7.11 | — |
| FY2019 | −$9.71 | — |
| FY2018 | −$5.46 | — |
| FY2017 | −$0.86 | — |
| FY2016 | −$5.49 | — |
Quarterly newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| Sep 2026 | −$0.27 | — |
| Jun 2026 | −$0.05 | — |
| Mar 2026 | $2.88 | — |
| Dec 2025 | −$3.93 | — |
| 43 more quarters | Free account |
Against its own ten years
EPS (diluted) against peers
| Company | EPS (diluted) |
|---|---|
| HRMY Harmony Biosciences Holdings, Inc. compare | $3.02 |
| TRVI Trevi Therapeutics, Inc. compare | −$0.34 |
| MRVI Maravai LifeSciences Holdings, Inc. compare | −$0.43 |
| MESO Mesoblast Limited compare | −$1.12 |
| VIR Vir Biotechnology, Inc. compare | −$1.26 |
| SRPT Sarepta Therapeutics, Inc. | −$1.37 |
| MAZE Maze Therapeutics, Inc. compare | −$2.52 |
| REPL Replimune Group, Inc. compare | −$2.79 |
| TRAX First Tracks Biotherapeutics, Inc. compare | −$5.17 |
What EPS (diluted) is
Diluted EPS tells an investor how much profit a company earned for each share, counting the extra shares that options and convertible securities could create.
Reported line item